Patient-Centric & Prospective Medicine Project

The Center for Medicine in the Public Interest (CMPI) has initiated a research program to study the treatment preferences of patients with Idiopathic pulmonary fibrosis (IPF). The project is supported by Intermune, a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Dr. John F P Bridges PhD, an Associate Professor at the Johns Hopkins Bloomberg School of Public Health and Senior Fellow at CMPI, will serve as the principal investigator of this project. The project will apply the principles of community-based participatory medicine to engage patients, family members, providers and other stakeholder in the design and pilot of a survey instrument to measure the stated-preferences of patients of with IPF for the potential benefits and risk of therapy. A geographically diverse sample of patients with IPF will be then recruited through clinics and advocacy groups to complete the survey. Analysis will use state-of-the-art methods to estimate preferences and results will be disseminated widely.
Sign Up for Our Email Newsletter


Peter Pitts on WOR 710
  • WOR 710
  • 04/11/2017

Peter Pitts on WOR 710 "In The Arena"

CMPI President Peter Pitts weighs in on the healthcare debate...  Read more

Patients vs PBMs: The Movie
  • CMPI
  • 07/14/2017

Patients vs PBMs: The Movie

Patients vs PBMs: The Movie ...  Read more

ICER Devalues People With Rheumatoid Arthritis

ICER Devalues People With Rheumatoid Arthritis

ICER's 'studies' are the cold fusion experiments of health care economics. ...  Read more